The Motley Fool EN

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.

Mar 13, 2026 &03281313202631; 14:28 UTC www.fool.com Trending 4/5

Read original on www.fool.com ↗

↗

Positive for markets

Sentiment score: +75/100

High impact Medium-term (weeks)

WHAT THIS MEANS

A major fund has made a $170 million investment in Celcuity, a biotech company whose stock has surged 1,040% in the past year, driven by FDA review progress for its breast cancer drug candidate. This significant institutional backing reflects strong confidence in the company's precision oncology platform and potential regulatory approval.

AI CONFIDENCE

78% High

SENTIMENT GAUGE

NEWS POWER SCORE

AFFECTED ASSETS

↑

CELC

CELCStock

Expected to rise

Major institutional investment of $170M signals strong confidence; FDA review for breast cancer drug represents significant value catalyst; 1,040% YTD performance demonstrates market enthusiasm for precision oncology approach

↑

S&P 500

^GSPCIndex

Expected to rise

Biotech sector strength and positive FDA regulatory developments support broader healthcare equity gains

↑

Biotech SPDR

XBIIndex

Expected to rise

Biotech ETF benefits from positive sentiment in precision oncology and successful drug development pipeline

PRICE HISTORY

Loading chart...

⚡ SUGGESTED ACTION

Monitor FDA decision timeline closely as primary catalyst; consider entry on any pullback given strong institutional backing and precision oncology tailwinds. Risk management essential given extreme valuation after 1,040% run-up; position sizing should reflect binary regulatory outcome risk.

KEY SIGNALS

Large institutional capital deployment ($170M fund investment)FDA regulatory review in progress for breast cancer therapeuticExceptional stock performance (1,040% YTY) indicating market validationProprietary precision oncology technology platformPotential near-term catalyst from FDA decision

SECTORS INVOLVED

BiotechnologyHealthcarePharmaceuticalsPrecision Medicine

Analysis generated on Mar 16, 2026 at 14:10 UTC

Disclaimer: This analysis is generated by artificial intelligence for informational purposes only and does not constitute financial advice, investment recommendation, or solicitation. Original reporting by The Motley Fool. Always conduct your own research and consult a qualified financial advisor before making investment decisions.

Inside One Fund's $170 Million Bet on a Biotech Stock Up 1,040% in a Year Amid FDA Review for Breast Cancer Drug

RELATED INTELLIGENCE